Calan (Verapamil Injection) and Delavirdine
Determining the interaction of Calan (Verapamil Injection) and Delavirdine and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Delavirdine may increase the blood levels and effects of verapamil. You may be more likely to experience serious side effects such as irregular heart rhythm, fluid retention, swelling, heart failure, and excessively low blood pressure. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek medical attention if you develop dizziness or fainting; sudden, unexplained weight gain; swelling of the hands, ankles, or feet; chest pain; or difficulty breathing during treatment with these medications. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with delavirdine may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves delavirdine inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most calcium channel blockers.
MANAGEMENT: Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with delavirdine. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.
- "Product Information. Rescriptor (delavirdine)." Pharmacia and Upjohn, Kalamazoo, MI.
Generic Name: verapamil
Brand name: Calan, Calan SR, Isoptin SR, Verelan, Isoptin, Isoptin IV, Covera-HS, Verelan PM
Synonyms: Calan Immediate-Release Tablets, Calan
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Calan (Verapamil Injection)-Delavirdine Mesylate
- Calan (Verapamil Injection)-Delestrogen
- Calan (Verapamil Injection)-Delestrogen injection
- Calan (Verapamil Injection)-Delos Liquid
- Calan (Verapamil Injection)-Delos Lotion
- Calan (Verapamil Injection)-Delstrigo
- Delavirdine-Calan SR
- Delavirdine-Calaspargase Pegol
- Delavirdine-Calaspargase Pegol-mknl
- Delavirdine-Calci-Chew
- Delavirdine-Calcibind
- Delavirdine-Calcidol